Hospital operator HCA Healthcare (NYSE: HCA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 8.7% year on year to $20.23 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ estimates. Its GAAP profit of $7.62 per share was 2.2% above analysts’ consensus estimates.

Is now the time to buy HCA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

HCA Healthcare delivered solid results in the second quarter, with revenue and earnings per share both ahead of Wall Street expectations. The positive market reaction reflected management’s ability to navigate significant headwinds, particularly an unexpected increase in uninsured patient volumes following the expiration of enhanced premium tax credits. CEO Samuel N. Hazen highlighted that while overall patient demand remained robust—especially for emergency services—unfavorable payer mix shifts put pressure on margins as more patients migrated from insurance exchanges to uninsured status. Hazen noted, “Adjusted admissions for patients who were formerly covered by the health insurance exchanges declined by 15%,” with nearly all of those patients becoming uninsured.

Looking ahead, HCA’s updated guidance is shaped by persistent uncertainty around insurance coverage trends, ongoing payer mix challenges, and the company’s ongoing cost management initiatives. Management signaled that the loss of enhanced premium tax credits will continue to affect volumes and profitability in several key markets, with CFO Michael A. Marks stating, “The variables on the exchanges are difficult to predict and require significant judgments.” Hazen pointed to investments in capacity expansion and digital transformation as critical to supporting long-term growth and mitigating margin pressures, while also acknowledging that potential regulatory changes—such as Medicaid work requirements—could add further complexity in 2027 and beyond.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong patient demand in core services, a sharp shift in uninsured volumes, and disciplined expense management through resiliency programs.

• Uninsured volumes surged: HCA saw a significant increase in uninsured patient admissions, primarily due to the expiration of enhanced premium tax credits. Nearly all patients losing exchange coverage became uninsured, which accounted for about 80% of the growth in uninsured volumes, creating a negative impact on margins and adjusted EBITDA.
• Demand strength in emergency services: Despite payer mix headwinds, insured patient volumes excluding exchanges remained solid, with notable growth in emergency room visits, cardiac procedures, and rehabilitation services. Management cited strong demographic trends and population growth in core markets like Florida, Texas, and Georgia as drivers of sustained demand.
• Elective surgery softness: Declines in both inpatient and outpatient elective surgeries were attributed to affordability challenges and the loss of exchange coverage, as well as broader macroeconomic pressures. Emergent surgical cases, however, continued to grow, offsetting some of the weakness in electives.
• Medicaid supplemental payments buffered impact: HCA benefited from incremental net Medicaid supplemental payments, especially from a recently approved Florida program, which provided a $540 million benefit that partially offset the negative impact from uninsured volumes. Management emphasized the importance of these payments in supporting access to care amid rising uncompensated care.
• Cost controls and resiliency programs: The company continued to make progress with its financial resiliency initiatives, which include digital transformation, operational efficiencies, and expanded global capabilities. These efforts helped keep cost per admission flat year-over-year, despite inflation and higher professional fees in areas like anesthesia and radiology.

Drivers of Future Performance

HCA’s outlook is shaped by ongoing payer mix shifts, continued investment in network capacity, and execution of cost control initiatives.

• Coverage trends and payer mix risk: Management expects continued financial pressure from the elevated uninsured population as more patients lose exchange coverage, especially in divisions with high exposure. The company’s guidance assumes the unfavorable impact from this migration will persist through the rest of the year, with some moderation possible if policy changes or patient coverage transitions emerge.
• Capacity expansion and market growth: HCA is investing over $7 billion in new inpatient beds and outpatient care sites across growth markets. Management believes these investments, alongside positive demographic trends, will support long-term demand, strengthen competitive positioning, and provide a buffer against market volatility.
• Cost management and digital transformation: The ongoing financial resiliency program—emphasizing digital tools, global operations, and enhanced workforce strategies—is expected to generate multi-year cost efficiencies. Management remains focused on bending the cost curve to offset pressures from payer mix and professional fees, while also preparing for potential regulatory changes such as Medicaid work requirements in 2027.

Catalysts in Upcoming Quarters

Going forward, our analysts will be monitoring (1) the pace and impact of uninsured volume growth and its effect on payer mix, (2) the realization and durability of cost savings from HCA’s financial resiliency and digital initiatives, and (3) the execution of capacity expansions and demographic-driven demand in high-growth markets. Regulatory developments and further payer mix shifts will also be critical to watch.

HCA Healthcare currently trades at $381.43, up from $376.50 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.